Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Xencor's Vudalimab?
Vudalimab is a monoclonal antibody commercialized by Xencor, with a leading Phase II program in Cervical Cancer. According to Globaldata,...
Vudalimab by Xencor for Cervical Cancer: Likelihood of Approval
Vudalimab is under clinical development by Xencor and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Vudalimab by Xencor for Nasopharyngeal Cancer: Likelihood of Approval
Vudalimab is under clinical development by Xencor and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...
Vudalimab by Xencor for Non-Small Cell Lung Cancer: Likelihood of Approval
Vudalimab is under clinical development by Xencor and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...